Tyrosinase-related protein 2 and Glycoprotein 100 peptide-HLA complexes (TRP-2/gp100-HLA complex)

The target consists of specific peptide epitopes derived from Tyrosinase-related protein 2 (TRP-2) and Glycoprotein 100 (gp100) that are presented on the cell surface by Human Leukocyte Antigen (HLA) molecules, most commonly HLA-A*02:01. TRP-2 (also known as Dopachrome tautomerase) and gp100 (also known as PMEL) are melanocyte differentiation antigens essential for melanin biosynthesis and the maturation of melanosomes [UniProt P40126, P40837]. These proteins are frequently overexpressed in melanoma, and their HLA-presented peptides serve as critical recognition signals for the cellular immune system, specifically CD8+ cytotoxic T lymphocytes [PubMed 10426998]. Therapeutic strategies targeting these complexes, such as TCR-engineered T-cells and bispecific T-cell engagers like Tebentafusp, aim to harness the specificity of T-cell receptors to selectively destroy malignant cells [PubMed 34554117]. Because these antigens are also expressed in healthy melanocytes in the skin, eyes, and inner ear, clinical use of these therapies often results in on-target, off-tumor toxicities, including vitiligo and uveitis [PubMed 11544351]. Monitoring for HLA-A*02:01 expression is essential for patient selection, as many of these therapies are allele-specific. Overall, these peptide-HLA complexes represent a cornerstone of modern melanoma immunotherapy, bridging the gap between intracellular protein expression and extracellular immune detection.

Other names

DCT/PMEL-HLA complexesMelanocyte differentiation antigen-HLA complexesTRP-2/gp100 epitopesDopachrome tautomerase and Premelanosome protein epitopesMelanoma-associated antigen (MAA) epitopes

T-cell receptor (TCR) mediated recognition of the peptide-HLA complex, leading to T-cell activation and cytotoxic lysis of the target cell via perforin and granzyme release.